Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
309M
-
Number of holders
-
280
-
Total 13F shares, excl. options
-
309M
-
Shares change
-
+4.54M
-
Total reported value, excl. options
-
$2.53B
-
Value change
-
+$26.4M
-
Put/Call ratio
-
1.52
-
Number of buys
-
149
-
Number of sells
-
-126
-
Price
-
$8.16
Significant Holders of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) as of Q1 2025
341 filings reported holding FOLD - AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share as of Q1 2025.
AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) has 280 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 309M shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (29.2M shares), VANGUARD GROUP INC (29.1M shares), BlackRock, Inc. (27.8M shares), PERCEPTIVE ADVISORS LLC (21.5M shares), Avoro Capital Advisors LLC (20.5M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (14.8M shares), Redmile Group, LLC (9.53M shares), STATE STREET CORP (9.52M shares), CITADEL ADVISORS LLC (7.84M shares), and Palo Alto Investors LP (7.35M shares).
This table shows the top 280 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.